Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.


Results 61-70 of 184 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2012Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib responseWhite, D.; Hughes, T.
2013Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagySchafranek, L.; Leclercq, T.; White, D.; Hughes, T.
2008Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemiale Coutre, P.; Ottmann, O.; Giles, F.; Kim, D.; Cortes, J.; Gattermann, N.; Apperley, J.; Larson, R.; Abruzzese, E.; O'Brien, S.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F.; Saglio, G.; Gobbi, M.; Kwong, Y.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J.; et al.
2006Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib eraGrigg, A.; Hughes, T.
2006Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: Back to the benchHui, C.; Hughes, T.
2007Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugsWhite, D.; Saunders, V.; Quinn, S.; Manley, P.; Hughes, T.
2008Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia?Hughes, T.
2010A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be AppropriateBranford, S.; Goh, H.; Izzo, B.; Beppu, L.; Ortmann, C.; Duniec, K.; Jin, Y.; Woodman, R.; Pane, F.; Kim, D.; Radich, J.; Hughes, T.; American Society of Hematology Meeting (52nd : 2010 : Florida, CA.)
2017Increased peroxisome proliferator-activated receptor γ activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cellsWang, J.; Lu, L.; Kok, C.; Saunders, V.; Goyne, J.; Dang, P.; Leclercq, T.; Hughes, T.; White, D.
2017A method for next-generation sequencing of paired diagnostic and remission Samples to detect mitochondrial DNA mutations associated with leukemiaPagani, I.; Kok, C.; Saunders, V.; Van der Hoek, M.; Heatley, S.; Schwarer, A.; Hahn, C.; Hughes, T.; White, D.; Ross, D.